ACELRX PHARMACEUT. DL-01 Asset Resilience Ratio
ACELRX PHARMACEUT. DL-01 asset resilience ratio. ACELRX PHARMACEUT. DL-01 (R5XA) has an Asset Resilience Ratio of 48.75% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of ACELRX PHARMACEUT. DL-01 to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ACELRX PHARMACEUT. DL-01 (2021–2025)
Asset resilience ratio of ACELRX PHARMACEUT. DL-01 from 2021 to 2025. This chart shows how ACELRX PHARMACEUT. DL-01's Asset Resilience Ratio has changed over time. Read R5XA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ACELRX PHARMACEUT. DL-01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of ACELRX PHARMACEUT. DL-01.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €14.49 Million | 48.75% |
| Total Liquid Assets | €14.49 Million | 48.75% |
Asset Resilience Insights
- Very High Liquidity: ACELRX PHARMACEUT. DL-01 maintains exceptional liquid asset reserves at 48.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ACELRX PHARMACEUT. DL-01 Industry Peers by Asset Resilience Ratio
Compare ACELRX PHARMACEUT. DL-01's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
ACELRX PHARMACEUT. DL-01 Asset Resilience Ratio by Year (2021–2025)
ACELRX PHARMACEUT. DL-01 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for ACELRX PHARMACEUT. DL-01.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.75% | €14.49 Million ≈ $16.94 Million |
€29.72 Million ≈ $34.74 Million |
-- |
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€18.24 Million ≈ $21.32 Million |
-- |
| 2023-12-31 | 17.95% | €3.66 Million ≈ $4.28 Million |
€20.39 Million ≈ $23.84 Million |
+16.90pp |
| 2022-12-31 | 1.04% | €495.00K ≈ $578.71K |
€47.49 Million ≈ $55.52 Million |
-48.98pp |
| 2021-12-31 | 50.03% | €38.97 Million ≈ $45.56 Million |
€77.89 Million ≈ $91.07 Million |
-- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more